Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial

Li, Y.; Sun, Qiuning; He, Zhiwei; Fu, Lanqin; He, Chun‐Xia; Yan, Yuxin

doi:10.1111/jdv.12209

Cited by 43 publications

(35 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3] Furthermore, a preliminary study of 2 tablets of compounded TA administered 3 times per day reported that improvement occurred in 85% of patients in 4 weeks, 97% in 8 and 12 weeks, and 100% in 16 weeks. [4] TA is a synthetic lysine analog that inhibits plasmin activity, which has been used as an antifibrinolytic agent for over 30 years. The side effects of oral TA remain a concern.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma

Ma²,

Juliandri³

et al. 2017

Medicine

View full text Add to dashboard Cite

To evaluate the efficacy of a functional microarray of microneedles (MNs) plus topical tranexamic acid (TA) for melasma in middle-aged women in China.Thirty female subjects with melasma were enrolled in this study. The left or right side of the face was chosen randomly to be pretreated with a functional microarray of MNs, followed by topical 0.5% TA solution once per week for 12 weeks. The other half-face was the control, treated with a sham device plus topical 0.5% TA solution. At baseline and at weeks 4, 8, and 12 of treatment, clinical (photographic) evaluations and parameters determined by Visia were recorded. At baseline and week 12, patient satisfaction scores and the biophysical parameters measured by Mexameter were also recorded. Side effects were evaluated at baseline and at the end of the 12 weeks.In total, 28 women (93.3%) completed the study. The brown spots’ scores measured by Visia were significantly lower on the combined therapy side than on the control side at 12 weeks after starting treatment; there was no significant difference between sides at 4 or 8 weeks. After 12 weeks, melanin index (MI) decreased significantly in both 2 groups, and the MI was significantly less on the combined side at week 12. Transepidermal water loss, roughness, skin hydration, skin elasticity, and erythema index showed no significant differences between 2 sides at baseline, 4, 8, and 12 weeks after treatment. Physicians’ evaluations of photographs showed better results at week 12 with combined therapy: >25% improvement was observed in the MNs plus TA side in 25 patients, and in the TA side in only 10 patients. Subjective satisfaction scores on both sides increased significantly. The participants were more satisfied with the results of the combined therapy side than the control side. No obvious adverse reactions were observed throughout the study.Combined therapy with a functional microarray of MNs and topical TA solution is a promising treatment for melasma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Tranexamic acid (TA), a plasmin inhibitor, is reported to improve melasma when administrated orally [3,4] or injected locally. [5] Long-term oral administration of TA may be associated with gastrointestinal adverse effects and an increased risk of thrombosis.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma

Ma²,

Juliandri³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Li et al 97 emphasized that this plasmin inhibitor has a greater effect on the affected melasmic skin than on normal skin and that this was due to the greater amount of vasculature and mast cells in the affected skin. They also pointed out that mast cell tryptase degrades basement lamina collagen type IV.…”

Section: Melasma: a Model Of Incontinencementioning

confidence: 99%

Disorders of Pigmentation of the Skin - Hypotheses Underlying Interventions by Multiple Systems of Medicine:Is there a Role for Integrated Medicine?

Arianayagam

Ryan

2016

Current Science

View full text Add to dashboard Cite

Biomedicine has not provided a complete explanation with fully effective therapies for disorders of pigmentation. Biomedicine emphasizes the role of melanocyte for protection from UV rays and as a determinant of skin colour. These important properties acquired a genetic basis much later than other functions, many relating to cell contact as in the keratinocyte -melanocyte unit, or as with the synapses of the neurological system. There are other roles, biochemical and mechanical, of melanocyte. Management that is inclusive of a maximally holistic approach justifies the use of diverse herbals, yoga and concern for cultural awareness provided by integrated medicine. Vitiligo provides a model which demonstrates that Ayurveda has a richer view of its presentations, possibly a stronger line on its pathogenesis, and a huge range of herbals, many now backed by studies from ethnobotanical laboratories, awaiting research into the many possible mechanisms by which they may act in the wide and complex field of melanocyte biochemistry.

show abstract

“…However, the promise of TXA used in whatever form (oral, topical etc) is yet to be translated into clinical evidence. The data from small, uncontrolled, open trials point to a very modest, very short-term improvement and nothing more [10].…”

mentioning

confidence: 99%

Agenda for Future Research in Melasma: QUO VADIS?

Panda¹

2014

Pigmentary Disorders

View full text Add to dashboard Cite

Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial

Cited by 43 publications

References 3 publications

Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma

Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma

Disorders of Pigmentation of the Skin - Hypotheses Underlying Interventions by Multiple Systems of Medicine:Is there a Role for Integrated Medicine?

Agenda for Future Research in Melasma: QUO VADIS?

Contact Info

Product

Resources

About